Cargando…

Clinicopathological factors affecting the effect of neoadjuvant chemotherapy in patients with gastric cancer

BACKGROUND: Neoadjuvant chemotherapy is an important part of the comprehensive treatment of advanced gastric cancer (GC). The effect of neoadjuvant chemotherapy plays a key role in the prognosis of GC patients. Pathological response can represent the effect of neoadjuvant chemotherapy. However, evid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Lin, Ma, Zhiqiang, Ye, Xin, Kang, Weiming, Yu, Jianchun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7874458/ https://www.ncbi.nlm.nih.gov/pubmed/33563277 http://dx.doi.org/10.1186/s12957-021-02157-x

Ejemplares similares

Risk Factors for Postoperative Infectious Complications in Elderly Patients with Gastric Cancer
por: Liu, Xiao, et al.
Publicado: (2020)

The Sensitivity Prediction of Neoadjuvant Chemotherapy for Gastric Cancer
por: Sun, Juan, et al.
Publicado: (2021)

Risk factors for cancer-specific survival in elderly gastric cancer patients after curative gastrectomy
por: Liu, Xiao, et al.
Publicado: (2022)

Visceral Adipose Tissue Assessment Enhances the Prognostic Value of GLIM Criteria in Patients with Gastric Cancer Undergoing Radical Gastrectomy after Neoadjuvant Treatment
por: Zhang, Yingjing, et al.
Publicado: (2022)

Clinicopathological risk factors for recurrence after neoadjuvant chemotherapy and radical hysterectomy in cervical cancer
por: Wang, Huali, et al.
Publicado: (2013)

Long non-coding RNA HNF1A-AS1 induces 5-FU resistance of gastric cancer through miR-30b-5p/EIF5A2 pathway
por: Jiang, Lin, et al.
Publicado: (2022)

Perioperative chemotherapy versus adjuvant chemotherapy treatment for resectable locally advanced gastric cancer: a retrospective cohort study
por: Su, Pengfei, et al.
Publicado: (2023)

Clinicopathological and prognostic significance of high circulating lymphocyte ratio in patients receiving neoadjuvant chemotherapy for advanced gastric cancer
por: Li, Yang, et al.
Publicado: (2018)

Monitoring early responses to neoadjuvant chemotherapy and the factors affecting neoadjuvant chemotherapy responses in primary osteosarcoma
por: Yu, Hong, et al.
Publicado: (2023)

Timing of surgery after neoadjuvant chemotherapy for gastric cancer: Impact on outcomes
por: Liu, Yi, et al.
Publicado: (2018)

Pathological evaluation of neoadjuvant chemotherapy in advanced gastric cancer
por: Hu, Shen-Bao, et al.
Publicado: (2019)

Can Gastric Cancer Patients with High Mandard Score Benefit from Neoadjuvant Chemotherapy?
por: Kang, Wen-Zhe, et al.
Publicado: (2022)

Neoadjuvant Chemotherapy in Asian Patients With Locally Advanced Gastric Cancer
por: Tong, Xie, et al.
Publicado: (2023)

Effect of neoadjuvant chemotherapy combined with hyperthermic intraperitoneal perfusion chemotherapy on advanced gastric cancer
por: CUI, HAI-BIN, et al.
Publicado: (2014)

Perioperative versus total neoadjuvant chemotherapy in gastric cancer
por: Yang, Jessica, et al.
Publicado: (2023)

A Retrospective Study of Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer
por: Wang, Yajing, et al.
Publicado: (2020)

Risk Factors and Prognostic Impact of Postoperative Complications in Patients with Advanced Gastric Cancer Receiving Neoadjuvant Chemotherapy
por: Yu, Hong, et al.
Publicado: (2022)

Comparisons of nutritional status and complications between patients with and without postoperative feeding jejunostomy tube in gastric cancer: a retrospective study
por: Li, Kang, et al.
Publicado: (2023)

Baseline splenic volume as a biomarker for clinical outcome and circulating lymphocyte count in gastric cancer
por: Zeng, Ziyang, et al.
Publicado: (2023)

Neoadjuvant Intraperitoneal and Systemic Chemotherapy Versus Neoadjuvant Systemic Chemotherapy With Docetaxel, Oxaliplatin, and S-1 for Gastric Cancer With Peritoneal Metastasis: A Propensity Score Matched Analysis
por: Zhang, Xin, et al.
Publicado: (2021)

Association of Adjuvant Chemotherapy With Overall Survival Among Patients With Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy
por: Lin, Jian-Xian, et al.
Publicado: (2022)

Microsatellite Status Affects Tumor Response and Survival in Patients Undergoing Neoadjuvant Chemotherapy for Clinical Stage III Gastric Cancer
por: Cai, Zhenghao, et al.
Publicado: (2020)

Neoadjuvant chemotherapy for gastric cancer. Is it a must or a fake?
por: Reddavid, Rossella, et al.
Publicado: (2018)

Response Evaluation after Neoadjuvant Chemotherapy for Resectable Gastric Cancer
por: Sandø, Alina Desiree, et al.
Publicado: (2023)

Body composition parameters for predicting the efficacy of neoadjuvant chemotherapy with immunotherapy for gastric cancer
por: Lin, Guang-Tan, et al.
Publicado: (2022)

CT-based radiomics scores predict response to neoadjuvant chemotherapy and survival in patients with gastric cancer
por: Sun, Kai-Yu, et al.
Publicado: (2020)

LACTB and LC3 could serve as potential biomarkers of gastric cancer to neoadjuvant chemotherapy with oxaliplatin plus S-1
por: Yang, Fang, et al.
Publicado: (2021)

Does postoperative chemotherapy improve overall survival of patients with ypT1-2N0 cancer?
por: Su, Pengfei, et al.
Publicado: (2022)

A Comparison of Clinicopathologic Outcomes Across Neoadjuvant and Adjuvant Treatment Modalities in Resectable Gastric Cancer
por: Anderson, Eric, et al.
Publicado: (2021)

Advanced gastric cancer: CT radiomics prediction and early detection of downstaging with neoadjuvant chemotherapy
por: Xu, Qinmei, et al.
Publicado: (2021)

Complications after radical gastrectomy following FOLFOX7 neoadjuvant chemotherapy for gastric cancer
por: Li, Zi-Yu, et al.
Publicado: (2011)

Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer
por: Li, Song, et al.
Publicado: (2023)

Optimal timing of surgery for gastric cancer after neoadjuvant chemotherapy: a systematic review and meta-analysis
por: Ling, Qi, et al.
Publicado: (2023)

Multi-omics characterization of molecular features of gastric cancer correlated with response to neoadjuvant chemotherapy
por: Li, Ziyu, et al.
Publicado: (2020)

Comparison of clinicopathological characteristics and response to neoadjuvant chemotherapy between HER2-low and HER2-zero breast cancer
por: Zhou, Shuling, et al.
Publicado: (2022)

Adjuvant chemotherapy may be unnecessary for ypT0-2N0 gastric cancer patients after neoadjuvant chemotherapy and curative gastrectomy
por: Shao, Xinxin, et al.
Publicado: (2023)

FOLFOX versus EOX as a neoadjuvant chemotherapy regimen for patients with advanced gastric cancer
por: CHEN, WENJUN, et al.
Publicado: (2014)

Prognostic Model of D2 Radical Gastrectomy Combined with Neoadjuvant Chemotherapy for Gastric Cancer
por: Wang, Guangjun, et al.
Publicado: (2023)

AKR1B10 expression predicts response of gastric cancer to neoadjuvant chemotherapy
por: Ahmed, Syed Minhaj Uddin, et al.
Publicado: (2019)

Effectiveness and Safety of Apatinib Plus Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer: A Nonrandomized Controlled Trial
por: Lin, Jian-Xian, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_chq5ita69pdd3rggg729nlng8l